Home › Rectal Cancer › NCT06565052
The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
Recruiting
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age greater than or equal to 18 years at time of enrollment. * English-Speaking. * Diagnosis of clinical stage II-III rectal cancer. * Planned, ongoing or just completed neoadjuvant treatment, including either 1) chemoradiation, 2) total neoadjuvant therapy (TNT), or 3) chemotherapy only; and anticipated surgical resection to follow. * Able to understand the study procedures, agree to participate in the study program, and voluntarily provide informed consent. Exclusion Criteria: * Distant metastatic disease known at the time of diagnosis. * Functional incapacity (i.e., incapable of performing exercise testing). * Comorbid conditions or cognitive/physical impairments that contraindicate exercise. * Currently undergoing treatment for a secondary primary tumor, in addition to primary rectal cancer. * Currently enrolled in a separate clinical trial that would prohibit them from performing the tasks instructed in this trial. * Currently participating in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described intervention, where additional exercise done regularly will contaminate the intervention effects.
About the study
The purpose of this study is to determine the feasibility of a prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant chemotherapy and/or radiation, followed by surgical resection.
The names of the groups in this research study are:
* Group A: Prehabilitation program * Group B: Usual Care
What is being tested
- Prehabilitation Program (behavioral)
Sponsor: Dana-Farber Cancer Institute · Participants: 40 · Started: Dec 15, 2024
Contact the study team
- Jeffrey Meyerhardt, MD, MPH · Phone: 617-632-6855
Official record on ClinicalTrials.gov — NCT06565052
Locations in the U.S.
| Massachusetts | Brigham and Women's Hospital, Boston Dana-Farber Cancer Institute, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.